Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The save study experience

American Heart Journal

Volumn 135, Issue 3, 1998, Pages 406-413

  Hager, W D ^a   Davis, B R ^a   Riba, A ^a   Moye, L A ^a   Wun, C C ^a   Rouleau, J L ^a   Lamas, G A ^a   Pfeffer, M A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031891273     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70315-1     Document Type: Article

References (28)

1. The Norwegian Multicenter Study Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 304 1981 801 807
2. A Hjalmarson D Elmfeldt J Herlitz S Holmberg I Malek G Nyberg Effect on mortality of metoprolol in acute myocardial infarction Lancet 2 1981 823 826
3. The Norwegian Multicenter Study Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 304 1981 801 807
4. The Steering Committee of the Physicians' Health Study Research Group Preliminary report: findings from the aspirin component of the ongoing physicians' health study N Engl J Med 318 1989 129 135
5. ISIS-2 Second International Study of Infarct Survival Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
6. MA Pfeffer E Braunwald LA Moye L Basta EJ Brown TE Cuddy on behalf of the SAVE investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial N Engl J Med 327 1992 669 677
7. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 319 1988 385 392
8. S Yusuf P Held C. Furberg Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies Am J Cardiol 91 1991 1295 1297
9. G Zuanetti R Latini F Avanzini MG Franzosi AP Maggioni F Colombo on behalf of the GISSI investigators Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI experience) Am J Cardiol 78 1996 153 157
10. ACC/AHA guidelines for the management of patients with acute myocardial infarction J Am Coll Cardiol 28 1996 1328 1428
11. RE Goldstein SJ Boccuzzi D Cruess S Nattel the Adverse Experience Committee and the Multicenter Diltiazem Postinfarction Research Group Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction Circulation 83 1991 52 60
12. LA Moye MA Pfeffer E. Braunwald Rationale, design and baseline characteristics of the survival and ventricular enlargement trial Am J Cardiol 68 1991 70D 79D
13. JD Kalbfleish RL. Prentice The statistical analysis of failure time data 1980 John Wiley &Sons New York
14. DR. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
15. The Israeli Sprint Study Group Secondary prevention reinfarction Israeli nifedipine trial: a randomized intervention trial of nifedipine in patients with acute myocardial infarction European Heart J 9 1988 354 364
16. U Goldbourt S Behar H Reicher-Reiss M Zion L Mandelzweig E Kaplinsky for the SPRINT Group Early administration of nifedipine in suspected acute myocardial infarction Arch Intern Med 153 1993 345 353
17. The Danish Study Group on Verapamil in Myocardial Infarction Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II—DAVIT II) Am J Cardiol 66 1990 779 785
18. CD Furberg BM Psaty JV. Meyer Nifedipine: dose-related increase in mortality in patients with coronary heart disease Circulation 92 1995 1326 1331
19. GA Lamas MA Pfeffer P Hamm J Wertheimer JL Rouleau E Braunwald for the SAVE Investigators Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 327 1992 241 247
20. S. Yusuf Calcium antagonists in coronary artery disease and hypertension Circulation 95 1995 1079 1082
21. S Braun V Boyko S Behar H Reicher-Reiss A Shotan Z Schlesinger on behalf of the Bezafibrate Infarction Prevention Study Participants Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients J Am Coll Cardiol 28 1996 7 11
22. WA Littler DJ Sheridan on behalf of the UK Study Group Placebo controlled trial of felodipine in patients with mild to moderate heart failure Br Heart J 73 1995 428 433
23. M Packer CM O'Connor JK Ghali ML Pressler PE Carson RN Belkin for the Prospective Randomized Amlodipine Survival Evaluation Study Group Effect of amlodipine on morbidity and mortality in severe chronic heart failure N Engl J Med 335 1996 1107 1114
24. BM Psaty SR Heckbert TD Koepsell DS Siscovick TE Raghunathan NS Weiss The risk of myocardial infarction associated with antihypertensive drug therapies JAMA 274 1995 620 625
25. NO Borhani M Mercuri PA Borheni VM Buckalew M Canossa-Terris AA Carr Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) JAMA 276 1996 785 791
26. WW. Parmley A delayed answer to the calcium blocker question J Am Coll Cardiol 27 1996 510 511
27. FH. Messerli Whatever happened to the calcium antagonist controversy? J Am Coll Cardiol 28 1996 12 13
28. BR Davis JA Cutler DJ Gordon CD Furberg JT Wright WC Cushman for the ALLHAT Research Group Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) Am J Hypertens 9 1996 342 360